Scientific Publication on Global Rubella

Print

Updated March 20, 2023

Related Pages

← Publications

These scientific publications are authored or co-authored by CDC scientists and/or funded by CDC’s Global Immunization Division, Center for Global Health.

2023

Nationwide measles and rubella outbreaks in South Sudan, 2019.
Peck ME, Maleghemi S, Kayembe L, et al. Open Forum Infect Dis. 2023;10(2):ofad032.

2022

How Australia's measles control activities have catalyzed rubella elimination.
Glynn-Robinson A, Knapp JK, Durrheim DN. International Journal of Infectious Diseases. 2022;114:72-78. doi: 10.1016/j.ijid.2021.11.003.

Feasibility of measles and rubella vaccination programmes for disease elimination: A modelling study.
Winter AK, Lambert B, Klein D, et al. Lancet Glob Health. 2022;10(10):E1412-E1422. doi: 10.1016/S2214-109X(22)00335-7.

Progress toward rubella and congenital rubella syndrome control and elimination — Worldwide, 2012-2020.
Zimmerman LA, Knapp JK, Antoni S, Grant GB, and Reef SE. MMWR Morb Mortal Wkly Rep. 2022;71(6):196-201. doi: 10.15585/mmwr.mm7106a2.

Top of Page

2021

Feasibility assessment of measles and rubella eradication.
Moss WJ, Shendale S, Lindstrand A, et al. Vaccine. 2021;39(27):3544-3559. doi: 10.1016/j.vaccine.2021.04.027.

Progress toward rubella elimination — World Health Organization European Region, 2005–2019.
O’Connor P, Yankovic D, Zimmerman L, Ben Mamou M, Reef S. MMWR Morb Mortal Wkly Rep. 2021;70:833–839. doi: 10.15585/mmwr.mm7023a1.

Assessing the burden of congenital rubella syndrome in China and evaluating mitigation strategies: A metapopulation modelling study.
Su Q, Feng Z, Hao L, et al. Lancet Infect Dis. 2021;21(7):1004-1013. doi: 10.1016/S1473-3099(20)30475-8.

Top of Page

2020

The potential role of using vaccine patches to induce immunity: Platform and pathways to innovation and commercialization.
Badizadegan K, Goodson JL, Rota PA, Thompson KM. Expert Rev Vaccines. 2020;19(2):175–194. doi: 10.1080/14760584.2020.1732215.

Vaccination coverage survey and seroprevalence among forcibly displaced Rohingya children, Cox's Bazar, Bangladesh, 2018: A cross-sectional study.
Feldstein LR, Bennett SD, Estivariz CF, et al. PLoS Med. 2020;17(3):e1003071. doi: 10.1371/journal.pmed.1003071.

Recent setbacks in measles elimination: The importance of investing in innovations for immunizations.
Goodson JL. Pan Afr Med J. 2020;35(Suppl 1):15. doi: 10.11604/pamj.supp.2020.35.1.21740.

Progress toward rubella elimination — Western Pacific Region, 2000–2019.
Knapp JK, Mariano KM, Pastore R, et al. MMWR Morb Mortal Wkly Rep. 2020;69(24):744–750. doi: 10.15585/mmwr.mm6924a4.

The African Region early experience with structures for the verification of measles elimination — A review.
Masresha B, Luce R, Tanifum P, Lebo E, Dosseh A, Mihigo R. Pan Afr Med J. 2020;35(Suppl 1):1. doi: 10.11604/pamj.supp.2020.35.1.19061.

Seroprevalence of measles, rubella, tetanus, and diphtheria antibodies among children in Haiti, 2017.
Minta AA, Andre-Alboth J, Childs L, et al. Am J Trop Med Hyg. 2020;103(4):1717­–1725. doi: 10.4269/ajtmh.20-0112.

The epidemiology of rubella, 2007–2018: An ecological analysis of surveillance data.
Patel MK, Antoni S, Danovaro-Holliday MC, et al. Lancet Glob Health. 2020;8(11):e1399-e1407. doi: 10.1016/S2214-109X(20)30320-X.

A microneedle patch for measles and rubella vaccination: A game changer for achieving elimination.
Prausnitz MR, Goodson JL, Rota PA, Orenstein WA. Curr Opin Virol. 2020;41:68–76. doi: 10.1016/j.coviro.2020.05.005.

Top of Page

2019

Successes and challenges for preventing measles, mumps and rubella by vaccination.
Bankamp B, Hickman C, Icenogle JP, Rota PA. Curr Opin Virol. 2019;34:110–116. doi: 10.1016/j.coviro.2019.01.002.

Genetic characterization of measles and rubella viruses detected through global measles and rubella elimination surveillance, 2016­–2018.
Brown KE, Rota PA, Goodson JL, et al. MMWR Morb Mortal Wkly Rep. 2019;68(26):587-591. doi: 10.15585/mmwr.mm6826a3.

Accelerating measles and rubella elimination through research and innovation — Findings from the Measles & Rubella Initiative research prioritization process, 2016.
Grant GB, Masresha BG, Moss WJ, et al. Vaccine. 2019;37(38):5754–5761. doi: 10.1016/j.vaccine.2019.01.081.

Progress toward rubella and congenital rubella syndrome control and elimination — Worldwide, 2000–2018.
Grant GB, Desai S, Dumolard L, Kretsinger K, Reef SE. MMWR Morb Mortal Wkly Rep. 2019;68(39):855–859. doi: 10.15585/mmwr.mm6839a5.

Research priorities for accelerating progress toward measles and rubella elimination identified by a cross-sectional web-based survey.
Kriss JL, Grant GB, Moss WJ, et al. Vaccine. 2019;37(38): 5745–5753. doi: 10.1016/j.vaccine.2019.02.058.

Is there any harm in administering extra-doses of vaccine to a person? Excess doses of vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2007–2017.
Moro PL, Arana J, Marquez PL, et al. Vaccine. 2019;37(28):3730–3734. doi: 10.1016/j.vaccine.2019.04.088.

Assessment of economic burden of concurrent measles and rubella outbreaks, Romania, 2011–2012.
Njau J, Janta D, Stanescu A, et al. Emerg Infect Dis. 2019;25(6):1101-1109. doi: 10.3201/eid2506.180339.

Top of Page

Selection From Previous Years

Progress and challenges in measles and rubella elimination in the WHO European Region.
Datta SS, O'Connor PM, Jankovic D, et al. Vaccine. 2018;36(36):5408–5415. doi: 10.1016/j.vaccine.2017.06.042.

Use of the revised World Health Organization cluster survey methodology to classify measles-rubella vaccination campaign coverage in 47 counties in Kenya, 2016.
Subaiya S, Tabu C, N'ganga J, et al. PLoS One. 2018;13(7):e0199786. doi: 10.1371/journal.pone.0199786.

Rubella vaccine: A tale of appropriate caution and remarkable success.
Zimmerman LA, Reef SE, Orenstein WA. JAMA Pediatr. 2018;172(1):95–96. doi: 10.1001/jamapediatrics.2017.4178.

Top of Page